Title: Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma
Authors: Robak, Tadeusz ×
Huang, Huiqiang
Jin, Jie
Zhu, Jun
Liu, Ting
Samoilova, Olga
Pylypenko, Halyna
Verhoef, Gregor
Siritanaratkul, Noppadol
Osmanov, Evgenii
Alexeeva, Julia
Pereira, Juliana
Drach, Johannes
Mayer, Jiri
Hong, Xiaonan
Okamoto, Rumiko
Pei, Lixia
Rooney, Brendan
van de Velde, Helgi
Cavalli, Franco
LYM-3002 Investigators #
Issue Date: Mar-2015
Series Title: New England Journal of Medicine vol:372 issue:10 pages:944-53
Article number: 10.1056/NEJMoa1412096
Abstract: The proteasome inhibitor bortezomib was initially approved for the treatment of relapsed mantle-cell lymphoma. We investigated whether substituting bortezomib for vincristine in frontline therapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) could improve outcomes in patients with newly diagnosed mantle-cell lymphoma.
ISSN: 0028-4793
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Experimental Hematology (+)
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science